As research into therapies utilizing CTLA-4 and PD-1/PD-L1 blockade to treat melanoma has advanced, further targets have been sought out in an effort to overcome issues such as incomplete tumor regression or relapse following treatment. This evidence concerns the gene PDCD1 and neoplasm.